Key points
- Strong revenue growth of 25.6% to AUD 788.7m
- Operating EBITDA margin of 20.9%, up 0.8% vs FY25
- Solid growth in Operating Diluted EPS and Final Dividend per Share
- Well-positioned for future government initiatives
- Strong balance sheet with reduced leverage of 2.3x
Full summary
Integral Diagnostics Ltd (IDX) reported strong FY26 results with a 25.6% increase in revenue to AUD 788.7m. The company achieved an improved operating EBITDA margin of 20.9%, up 0.8% from FY25. Operating EBITDA grew by 30.3% to AUD 164.8m, and Operating NPAT increased by 50.1% to AUD 47.4m. The company also saw solid growth in Operating Diluted EPS by 23.6% to 12.6 cps and a 50.0% increase in the Final Dividend per Share to 6.0 cps. IDX is well-positioned to benefit from future government initiatives, including MRI de-regulation, the National Lung Cancer Screening Program, and the GP Bulk Billing Incentive Program. The company maintains a strong balance sheet with reduced leverage of 2.3x at the end of FY26.
Outlook
IDX is well-positioned to further support government initiatives to improve outcomes for patients and to deliver solid revenue growth and further margin expansion.